Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).
Ae Rang KimYao LuScott H OkunoDenise ReinkeOphélia MaertensJohn PerentesisMitali BasuPamela L WoltersThomas De RaedtSant ChawlaRashmi ChughBrian A Van TineGeraldine O'SullivanAlice ChenKaren CichowskiBrigitte C WidemannPublished in: Sarcoma (2020)
Despite promising preclinical rationale and tolerability of the combination therapy, no responses were observed, and the study did not meet parameters for further evaluation in MPNSTs. This trial was registered with (NCT02008877).